Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

Alternative Renal Denervation Devices – From Ablative Solutions to Verve

Presenter: Michael Weber

October 28, 2024

Presentation TCT 2021

Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension

Presenter: Michael A. Weber

November 04, 2021

News Conference News TCT 2019

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

Todd Neale

October 09, 2019

Presentation TCT 2019

The Essentials of Blood Pressure Measurement: Office, Home, and Ambulatory — And Why It Matters

Presenter: Michael Weber

September 28, 2019

News Daily News

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

Todd Neale

June 24, 2019

Presentation CDM 2018

The Hope and Promise of Renal Denervation

Presenter: Michael A.Weber

October 12, 2018

Presentation CDM 2018

Comparing the Hypertension Guidelines: Resolving the Controversies

Presenter: Michael A.Weber

October 12, 2018

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Todd Neale

September 25, 2018

Presentation TCT 2018

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

Presenter: Vasilios Papademetriou, Paul A. Sobotka, Michael A. Weber

September 24, 2018

Presentation TCT 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presenter: John A. Bittl, Bernard J. Gersh, Michael A. Weber

September 24, 2018

Presentation Controversies and Advances 2017

Rise, Fall And Resurrection of Renal Denervation

Presenter: Michael A. Weber

November 16, 2017

Presentation TCT 2017

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Presenter: Hiren Mistry, Michael A. Weber

October 31, 2017

Presentation TCT 2017

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Presenter: Hiren Mistry, Michael A. Weber, Michael Böhm

October 31, 2017

Presentation TCT 2017

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Vessix RE-INFORCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Uncontrolled Hypertension Management Issues: Adherence, Testing, and Difficult Patient Scenarios

Presenter: Sidney C. Smith, Michael A. Weber

October 30, 2017

Presentation TCT 2017

What is the Optimal Therapy for Hypertension?

Presenter: Sidney C. Smith, Michael A. Weber

October 30, 2017

Presentation TCT 2017

Office, Home, or Ambulatory Blood Pressure: How to Measure Blood Pressure in Practice and Clinical Trials

Presenter: Sidney C. Smith, Michael A. Weber, C. Venkata S. Ram

October 30, 2017

Presentation TCT 2017

New U.S. Hypertension Guidelines and Treatment Targets

Presenter: Sidney C. Smith, Michael A. Weber, Sandra J Taler

October 30, 2017

Advertisement

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Alternative Renal Denervation Devices – From Ablative Solutions to Verve

Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

The Essentials of Blood Pressure Measurement: Office, Home, and Ambulatory — And Why It Matters

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

The Hope and Promise of Renal Denervation

Comparing the Hypertension Guidelines: Resolving the Controversies

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Rise, Fall And Resurrection of Renal Denervation

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?

Vessix RE-INFORCE Trial Update

Uncontrolled Hypertension Management Issues: Adherence, Testing, and Difficult Patient Scenarios

What is the Optimal Therapy for Hypertension?

Office, Home, or Ambulatory Blood Pressure: How to Measure Blood Pressure in Practice and Clinical Trials

New U.S. Hypertension Guidelines and Treatment Targets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content